eGenesis
E661990
eGenesis is a biotechnology company focused on using advanced gene-editing technologies to make animal organs safe and suitable for human transplantation.
All labels observed (1)
| Label | Occurrences |
|---|---|
| eGenesis canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7392986 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: eGenesis Context triple: [George Church, coFounded, eGenesis]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Yamanaka factors
Yamanaka factors are a set of transcription factors that can reprogram adult somatic cells into induced pluripotent stem cells, revolutionizing regenerative medicine and stem cell research.
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
H3 Biomedicine
H3 Biomedicine is a biotechnology company focused on discovering and developing precision cancer therapies using genomics-driven approaches.
-
E.
Regenesis Group
Regenesis Group is a sustainability-focused organization known for advancing green building and regenerative development practices.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: eGenesis Target entity description: eGenesis is a biotechnology company focused on using advanced gene-editing technologies to make animal organs safe and suitable for human transplantation.
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Yamanaka factors
Yamanaka factors are a set of transcription factors that can reprogram adult somatic cells into induced pluripotent stem cells, revolutionizing regenerative medicine and stem cell research.
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
H3 Biomedicine
H3 Biomedicine is a biotechnology company focused on discovering and developing precision cancer therapies using genomics-driven approaches.
-
E.
Regenesis Group
Regenesis Group is a sustainability-focused organization known for advancing green building and regenerative development practices.
- F. None of above. chosen
Statements (44)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| addressesProblem |
global shortage of transplantable human organs
ⓘ
immune rejection of xenotransplant organs ⓘ risk of cross-species viral transmission in xenotransplantation ⓘ |
| aim |
address organ shortage for human transplantation
ⓘ
eliminate porcine endogenous retroviruses from donor organs ⓘ reduce risk of organ rejection in xenotransplantation ⓘ |
| businessModel |
preclinical and clinical-stage biotech
ⓘ
therapeutic development ⓘ |
| collaboratesWith | academic medical centers for xenotransplantation research ⓘ |
| countryOfOrigin |
United States of America
ⓘ
surface form:
United States
|
| field |
gene editing
ⓘ
xenotransplantation ⓘ |
| focus |
developing xenotransplantation therapies
ⓘ
engineering donor animals for organ transplantation ⓘ making animal organs safe for human transplantation ⓘ |
| foundedBy |
George Church
NERFINISHED
ⓘ
Luhan Yang NERFINISHED ⓘ |
| foundedIn | 2015 ⓘ |
| hasEthicalConcernArea |
animal welfare in xenotransplantation
ⓘ
biosecurity of genetically modified animals ⓘ |
| hasFounderRole |
George Church is a co-founder of eGenesis
NERFINISHED
ⓘ
Luhan Yang is a co-founder of eGenesis NERFINISHED ⓘ |
| hasKeyPerson |
George Church
NERFINISHED
ⓘ
Luhan Yang NERFINISHED ⓘ |
| hasWebsite | https://www.egenesisbio.com/ ⓘ |
| headquartersLocation | Cambridge, Massachusetts, United States NERFINISHED ⓘ |
| industry | biotechnology ⓘ |
| productType |
genetically engineered donor organs
ⓘ
genetically modified pigs for organ donation ⓘ |
| regulatoryInteraction | works with regulators on xenotransplantation guidelines ⓘ |
| researchArea |
immunological compatibility between animal organs and humans
ⓘ
porcine-to-human organ transplantation ⓘ viral safety of xenotransplant organs ⓘ |
| scientificApproach |
insertion of human transgenes into donor animals
ⓘ
knockout of immunogenic pig genes ⓘ multiplex gene editing in pigs ⓘ |
| stage | clinical development in xenotransplantation ⓘ |
| targetPatientGroup | patients with end-stage organ failure ⓘ |
| usesTechnology |
CRISPR-based gene editing
ⓘ
advanced gene-editing technologies ⓘ |
| worksOnOrganType |
heart xenotransplantation
ⓘ
kidney xenotransplantation ⓘ liver xenotransplantation ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: eGenesis Description of subject: eGenesis is a biotechnology company focused on using advanced gene-editing technologies to make animal organs safe and suitable for human transplantation.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.